Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,172 GBX | -0.60% | -0.75% | +14.83% |
05-15 | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
05-14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.83% | 239B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Board Increases 2024 Dividend by 7% to $3.10 per Share